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ABSTRACT
Objectives: When study groups fail to publish their
results, a subsequent systematic review may come to
incorrect conclusions when combining information
only from published studies. p53 expression measured
by immunohistochemistry is a potential prognostic
factor in bladder cancer. Although numerous studies
have been conducted, its role is still under debate. The
assumption that unpublished studies too harbour
evidence on this research topic leads to the question
about the attributable effect when adding this
information and comparing it with published data.
Thus, the aim was to identify published and
unpublished studies and to explore their differences
potentially affecting the conclusion on its function as a
prognostic biomarker.
Design: Systematic review of published and
unpublished studies assessing p53 in bladder cancer
in Germany between 1993 and 2007.
Results: The systematic search revealed 16 studies of
which 11 (69%) have been published and 5 (31%)
have not. Key reason for not publishing the results was
a loss of interest of the investigators. There were no
obviously larger differences between published and
unpublished studies. However, a meaningful meta-
analysis was not possible mainly due to the poor (ie,
incomplete) reporting of study results.
Conclusions: Within this well-defined population of
studies, we could provide empirical evidence for the
failure of study groups to publish their results that was
mainly caused by loss of interest. This fact may be
coresponsible for the role of p53 as a prognostic factor
still being unclear. We consider p53 and the restriction
to studies in Germany as a specific example, but the
critical issues are probably similar for other prognostic
factors and other countries.
INTRODUCTION
In medical research, it is well accepted that a
single study is unlikely to provide a deﬁnite (or
ﬁnal) answer to clinical questions. Common
reasons are, for example, an insufﬁcient study
size or a limited representativeness with re-
spect to general practice.1–3 Particularly,
observational studies often used in prognos-
tic research generally provide rather weak
evidence because such studies are highly sus-
ceptible to various types of bias.3–5 Thus, it
is required to accumulate evidence by sys-
tematically reviewing relevant studies and, if
sensible, combining their results in a
meta-analysis. Such a review including subse-
quent analysis may provide an overall esti-
mate and an overview for the research
community, physicians and policymakers.
However, meta-analyses too are prone to bias
from several sources.2 6 In particular, a difﬁ-
cult situation emerges when observational
Strengths and limitations of this study
▪ According to our knowledge, this is the first
project which provides empirical evidence of
non-publication for a specific research question
due to loss of interest.
▪ The paradigm of p53 expression measured by
immunohistochemistry might be a valid model
choice to assess the extent of unpublished
studies in biomarker research but may not be
representative for other areas of medical
research.
▪ Although the project is based on extensive and
thorough search for published and unpublished
studies in Germany, it cannot be fully excluded
that relevant studies, whether published or
unpublished, have been missed.
▪ The geographic restriction to Germany was
necessary to achieve a comprehensive overview
on published and unpublished studies, but this
limits its general overall representativeness as
does its restriction regarding the period in which
studies were searched.
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studies compose the main source of evidence in certain
research ﬁelds including prognostic marker research.
Combining results from observational studies in a
meta-analysis is often complicated, especially because data
handling and statistical analysis frequently differ between
studies. In this context, the conduct of comprehensive
individual patient data (IPD) meta-analysis instead of a
meta-analysis of aggregated data gained importance.3 7 8
The basis of any successful review is always a systematic
literature search in respective electronic databases and
study registries with the aim to identify ideally all rele-
vant studies regarding a speciﬁc question of interest.
Obviously, the identiﬁcation of all relevant studies world-
wide is technically impossible. In addition, only rando-
mised controlled trials have to be registered but not
observational studies. Moreover, relevant studies might
be missed even with an extensive search because they
were not published for different reasons or at least not
published until the time of the search and are thus not
detectable in electronic databases or other sources.9 10 It
was reported that over 50% of the studies in biomedical
research were not fully published and thus represent
avoidable waste of research evidence.11 In case the
search revealed only a part of the conducted studies,
this may have an impact on the ﬁnal conclusions—
unless the identiﬁed studies that are included into a
meta-analysis compose an adequate sample.
Although empirical evidence is weak, it is likely that
several (observational) studies are unpublished, particu-
larly smaller and medium-sized studies. This might espe-
cially be the case when study groups fail to publish
because their results are not statistically signiﬁcant. The
speciﬁc problem that studies without signiﬁcant results
are less likely to be published has been termed as publi-
cation bias.12 13 The implication is that false-positive
results are over-represented in the literature, most likely
leading to an overestimation of the true prognostic
impact.14–17 Although the existence of unpublished
studies is well documented, the actual extent of unpub-
lished studies in a speciﬁc setting and its effect on the
derived conclusion is obviously difﬁcult to assess because
it appears impossible to appraise results of unpublished
and thus invisible studies.13 18 19
Since the early 1990s, p53 expression measured by
immunohistochemistry (short: p53) came into focus as a
potential biomarker for prognosis in patients with
cancers including bladder cancer.20–23 Although numer-
ous studies investigating the usefulness of p53 in bladder
cancer had been conducted, its prognostic impact is still
under debate, even after the conduction of several sys-
tematic reviews.24–28 In addition, there is clear evidence
that more studies have been performed than were even-
tually published.26 29
Two of the authors (BJSD, PJG) are actively involved
in the ﬁeld of marker research in bladder cancer and
also have extensive long-term connections to many uro-
logical departments, pathological institutes and the
respective scientiﬁc societies in Germany. Hence, it
became obvious that the topic of p53 and prognosis in
bladder cancer might represent a suitable setting to
investigate and assess the extent of unpublished data on
this topic and to evaluate their potential for publication
bias. To achieve a complete and comprehensive overview
on both, published and unpublished studies, we
restricted our attention to Germany and a limited time
period (1993–2007). A signiﬁcant number of studies ori-
ginate from this area and time period.24 Although such
restriction to a well-deﬁned population of studies
decreases the absolute number of studies, it may still
allow to estimate a combined effect unbiasedly though
with increased uncertainty. A systematic literature search
and the contacts of the two authors ensured the identiﬁ-
cation of nearly all studies which have been initiated.
In summary, the aim of this review was to identify all
published and unpublished studies investigating the role
of p53 in bladder cancer conducted over a 15-year
period in Germany, to explore the differences between
them and to evaluate the impact of the unpublished
studies on the interpretation of p53 as prognostic bio-
marker in patients with bladder cancer. In addition, the
reasons for not publishing results were evaluated.
METHODS
This analysis assessed studies (1) that investigated prog-
nostic impact of p53 in bladder cancer, and (2) that
were conducted in Germany through the years 1993–
2007. Since no patient data were retrieved, no approval
from institutional review board was obtained. The study
was initiated by three of the authors in 2005 and later
restarted in 2012 to ﬁnish the project.
Data retrieval
The aim of this step was to comprehensively retrieve a
complete survey comprising all studies with character-
istics as outlined above. To achieve this goal, an exten-
sive, systematic search was initiated using multiple
approaches and sources:
A. A systematic search in Medline was conducted in
2005 and again in 2007. The search is described in
ﬁgure 1. All hits were screened by BJSD and JBP and
potentially relevant articles were studied.
B. Assuming that this type of study is mostly performed
at university hospitals, a separate literature search was
launched focusing on chairmen or senior staff
members from all university hospitals in Germany
(BJSD, JBP).
C. Assuming that urologists must be involved in this
type of study, a questionnaire was sent to all urology
departments in Germany through the mail server of
the German Society of Urology (DGU) in 2006.
Chairmen and/or senior staff members from non-
responding institutions were personally contacted
subsequently (BJSD).
D. Programmes and conference proceedings for the study
period (grey literature search) were obtained from the
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German national meeting and, as far as possible, from
regional scientiﬁc urological societies (BJSD, JBP).
E. Furthermore, university hospital libraries were
searched via the internet for medical theses (doctoral
dissertation) studying the role of p53 in bladder
cancer in 2007 ( JBP).
F. Finally, the personal knowledge of two authors (PJG,
BJSD) extensively working in the ﬁeld allowed to
crosscheck with identiﬁed studies.
The different approaches are assumed to be sufﬁcient
to comprehensively identify all studies conducted in
Germany during the chosen period.
All reports that could not be retrieved by the thorough
literature search in Medline (A) were considered as
‘unpublished’. If an unpublished study was identiﬁed,
the researcher or the responsible faculty member was
personally contacted via email to ensure that the work
was still not published. If they did not respond to the
email, contact was established via phone. In addition,
the reason for non-publication was inquired. Obtained
answers (free text) were categorised. The status of
unpublished studies was checked again in May 2014.
Data extraction and analysis
From each study (published and unpublished), data for
a list of items were extracted by JBP and revised by PS.
Besides items on the manuscript level (reference, lan-
guage, reported institution), we extracted items on the
study level (type of study, recruitment period, assessed
biomarkers, p53 measurement, study size, tumour stage
and grade of included patients) as well as on the analysis
level (assessed outcomes, number of events, statistical
methods, analysis results). These items speciﬁcally
reﬂect the research question on p53 as potential prog-
nostic factor in bladder cancer. In the absence of a
standard tool to assess study quality of observational
studies, a formal assessment of study quality was not
done. However, extracted information from studies can
be used as an indicator for their quality in general.
All data were analysed in a descriptive way. The ori-
ginal intention was to present a combined estimate for
the prognostic effect of p53 on accepted end points,
including tumour recurrence, disease progression and
(overall or cancer-speciﬁc) survival based on published
literature, and to compare it to the unpublished results
to quantify potential publication bias. However, it
became clear in the course of the project that it was not
possible to provide any meaningful estimate, neither
based on published nor based on published and unpub-
lished data.
RESULTS
Data retrieval
The aim of the search was to identify all studies—
whether published or not—on p53 investigating the
prognosis of patients with bladder cancer in Germany
from 1993 to 2007. The results of the Medline searches
in 2005 and 2007 and the results of subsequent checks
are presented in ﬁgure 1. Altogether, 19 manuscripts
were selected and retrieved for data extraction.30–48
To identify possibly missing additional studies, a
simple questionnaire was sent to 345 urological depart-
ments in Germany in 2007 using the mail server of the
German Society of Urology (DGU). In total, 13 depart-
ments were excluded because these institutions were no
full urological departments but paediatric clinics, clinics
for rehabilitation, or only dedicated to diagnosis.
Feedback after two rounds of mailing comprised infor-
mation from 192 departments (57.8%). Personal contact
yielded response from another 76 institutions (22.9%).
For seven departments (2.1%) no information could be
obtained due to changes in staff and chairpersons. No
feedback was retrieved from another 57 departments
(17.2%). Altogether, information was retrieved from 268
institutions (80.7%). The feedback from university hos-
pitals was slightly higher than from non-academic institu-
tions (86.1% vs 80.1%, respectively).
In addition, programmes and congress proceedings
for the study period were obtained from the archives of
the DGU, comprising programmes of the national uro-
logical meetings, conferences on basic urological
science (Experimentelle Urologie) and from 11 add-
itional regional scientiﬁc urological societies. In
summary, 65 programmes from 90 identiﬁed meetings
within the relevant period (72%) could be analysed.
Access to medical theses from 12 of 35 (34.3%) univer-
sity libraries within Germany was obtained. Their con-
tents were examined for potentially relevant studies.
After crosschecking with studies identiﬁed in the
Medline search, ﬁve additional unpublished studies were
detected through the feedback to our survey (n=2),
review of medical conferences (n=3) and search for
medical theses in university libraries (n=2). Two studies
were identiﬁed through more than one source. There
Figure 1 Flow diagram of Medline search.
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was no other study according to the personal knowledge
and communication of two of the authors (PJG, BJSD).
Published studies
Issue: multiple reporting
Among 19 publications selected for data extraction,
several manuscripts were published by the same institu-
tion. Therefore, publications were checked for inde-
pendence. Publications originating from the same
institution with overlapping author lists, using p53 mea-
surements based on the same antibody and assessing
patients showing a similar spectrum regarding tumour
stage and tumour grade were considered as dependent.
Based on this deﬁnition, our comparison revealed 13
reports from 5 institutions with some potential overlap
in study populations. Owing to insufﬁcient information
(eg, regarding period of patient recruitment), we could
not assess the proportion of overlap in detail. For each
of these reports, the study comprising the largest data
set was selected for further analysis, whereas the remain-
ing eight studies were excluded. In the majority of cases,
this led to the most recent publication being chosen.
The only exceptions hereto were the two publications
from Hamburg37 42 and the two publications from
Cologne.30 40 In both cases, other markers had been
additionally considered in the more recent publication
but only on a smaller set of patients, presumably repre-
senting a subset of the population included in the ori-
ginal study.
Table 1(I) summarises all 19 publications including
the 8 manuscripts which were excluded because of pre-
sumed overlap in study populations.
Description of studies (n=11)
Included studies were published between 1993 and
2005. To our knowledge, the next study following this
period was published in 2009 and thus not considered
here.
From many reports, it remains unclear whether the
study was designed and conducted in a truly prospective
way or whether authors took advantage of archived spe-
cimens and patient information collected at regular
follow-ups in a more or less stringent fashion. Besides
diagnosis and partly speciﬁc therapy, three studies add-
itionally requested complete follow-up data (without
further speciﬁcation) or follow-up data of at least 2 years
for patient selection.39 41 47 The studies usually did not
describe patient selection in detail and thus did not
attempt to quantify the potential of selection bias that
might arise from missing specimens or other requested
data.
Information on tumour stage and tumour grade was
mostly reported showing some variation between the
studies (table 1(I)). While some studies focused on non-
muscle invasive bladder cancer, others investigated
advanced tumour stages or both. Similarly for tumour
grade, some studies included patients of any tumour
grade (G1–G4), while other studies focused on speciﬁc
grades (eg, only G2). Patients included in the published
studies came from the corresponding single centre
reporting the data. When reported, specimens were
derived through transurethral resection or cystectomy.
To detect p53 overexpression by immunohistochemis-
try, different antibodies with different dilutions had
been applied (table 2(I)). For analysis, the staining
results were categorised into the two categories of nega-
tive and positive results except for one study that used a
categorisation into four groups. Cut-offs varied from
study to study (range for binary cut-offs: 5–40%, table 2
(I)). In 7 out of 11 studies, the decisive reasons were not
provided. In the remaining publications, a reference was
provided as justiﬁcation (n=3) or the observed median
was used (n=1).
Samples sizes with respect to the prognostic analysis
were often small ranging from 30 to 119 patients
(median=69 patients, table 1(I)). If the number of
events of interest (recurrence, progression, death) repre-
senting the effective sample size of the study was at all
reported, it ranged between 11 and 63. Studies not
explicitly providing the number of events reported sur-
vival rates, median survival or some other related infor-
mation. The events were observed during follow-up of
varying length. Reported information on the individual
length of follow-up in patients ranged from 1 month
(=0.1 year) to 140 months (=11.7 years). None of the
published studies reported on any power or sample size
calculation to justify their (effective) size of population.
Statistical analysis and results
Binary end points (recurrence or progression) were ana-
lysed in two studies using the χ² test.30 43 All other nine
studies considered a time-to-event end point to assess
the prognostic impact of p53: overall survival (n=2),
cause-speciﬁc survival (n=2), recurrence-free survival
(n=2), progression-free survival (n=4) and combined
end point (tumour-free survival, n=1, cause-speciﬁc sur-
vival with preserved bladder, n=1). Four studies reported
results regarding two end points,39 41 43 47 and two
studies only presented results for subgroups.30 45 The
deﬁnition of the time to the event was provided as dur-
ation from initial diagnosis, surgical intervention or initi-
ation of chemotherapy to the event of interest in seven
studies (78%). For statistical analysis, authors applied
log-rank test (n=8) or Cox regression (univariate or
multivariate; n=6) for estimation of association.
A Kaplan–Meier graph was usually presented when the
log-rank test was applied.
Online supplementary tables S1 and S2 contain infor-
mation on reported analyses and their results of pub-
lished studies. Only two of six studies that used Cox
regression actually reported effect estimates in terms of
HRs.37 47 P values were reported by 6 of 11 studies,
while the other studies only provided information on sig-
niﬁcance as ‘smaller or greater than some value’ or even
described the result in words (eg, ‘not signiﬁcant’,
‘weakly correlated’).
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Table 1 Published and unpublished studies focusing on assessment of p53 as a potential prognostic factor in bladder
cancer
Reference (I) or contact person and
year of analysis (II)
Reporting
period*
Study size
(number of
events)
Tumour stage
Tumour grade Surgical treatment
(I) Published studies
Place of reporting institution: Düsseldorf (Germany)
Jankevicius et al (2002)45 NR 60 (NR)†
A: 39 (NR)
B: 21 (NR)
T1–T4
NR
TUR in 39 patients,
cystectomy in 21 patients
Schmitz-Dräger et al (1997)38 NR 61 (28) Ta–T4
G1–G3
NR
Schmitz-Dräger et al (1994)33‡ 1985–1993 43 (7) Ta–T4
G1–G3
NR
Place of reporting institution: Erlangen-Nürnberg and Halle (Germany)
Rödel et al (2000)41 1982–1996 70 (NR,NR)¶ T1–T4
G1–G4
TUR
Place of reporting institution: Hamburg (Germany)
Friedrich et al (1997)37 NR 53 (20) Ta–T1
G1–G3
TUR
Friedrich et al (2001)42‡ NR 40 (14) Ta, T1
G1–G3
TUR
Place of reporting institution: Hannover (Germany)
Serth et al (1995)36 NR 69 (13) T1
NR
TUR
Bokemeyer et al (1994)31‡ NR 41 (8) T1
NR
TUR
Kuczyk et al (1994)32‡ NR 41 (8) T1
G1–G2
TUR
Kuczyk et al (1995)§35‡ NR 41 (8) T1
G1–G2
TUR
Kuczyk et al (1995)34 NR 44 (23) T2–T4
G2–G3
cystectomy
Place of reporting institution: Cologne (Germany)
Hake et al (1993)§30 NR 119 (61)†
A: 40 (21)
B: 79 (40)
Ta, T1–T2
G1–G2
NR
Vorreuther et al (1997)40‡ 1978–1988 104 (53)**
A: 59 (29)
B: 45 (24)
C: 40 (22)
D: 64 (31)
Ta, T1
G1–G2
TUR
Place of reporting institution: Lübeck (Germany)
Krüger et al (2005)47 1988–1998 73 (52,27)¶ T1
G2–G3
TUR
Krüger et al (2003)46‡ 1987–1997 54 (43,19)¶ T1
G2–G3
TUR
Mahnken et al (2005)48‡ 1987–1999 69 (48,27)¶ T1
G2–G3
TUR
Place of reporting institution: Mainz (Germany)
Leissner et al (2001)43 1990–1997 70 (34,14)¶ Ta
G2
TUR
Place of reporting institution: Mainz and Magdeburg (Germany)
Wolf et al (2001)44 1989–1998 30 (11) T1–T4
G3
TUR in 5 patients, cystectomy
in 25 patients
Place of reporting institution: Münster (Germany)
van Ahlen et al (1997)§39 1988–1992 100 (NR,63)¶ Ta–T4
G1–G4
cystectomy
Continued
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Owing to the heterogeneity in study populations, dif-
ferent outcomes assessed and different statistical
methods applied, but, in particular, because of insufﬁ-
cient information on effect estimates or p values, a
meaningful meta-analysis cannot be conducted.
Although it might be possible to derive crude estimates
and p values based on reported numbers for some of
the studies, this kind of approach is (often) not sensible
for observational studies when effect estimates cannot
be adjusted for the presence of confounding factors.
Table 3(I) presents an overview regarding the ﬁnal
conclusion on the signiﬁcance of the impact of the p53
measures on the given end point. Considering all 17
reported analyses of the 11 included studies simultan-
eously, more than half of them (59%) revealed non-
signiﬁcant ﬁndings. Results show a similarly ambiguous
pattern, even when restricting analyses that included 69
(observed median of overall population size) or more
patients (effective samples size of 13–63 events; data not
shown). Studies reporting ‘signiﬁcant’ results, however,
consistently provide a trend towards a worse outcome for
patients with higher accumulated p53 measured by
immunohistochemistry.
Finally, when comparing results among the ﬁve institu-
tions publishing more than once, the reports per institu-
tion were generally consistent regarding their conclusion.
Overall quality of studies
As many items that we consider relevant in this setting
are incompletely/not reported by the authors of these
studies, the reporting quality is generally poor. As a con-
sequence, the quality of these studies cannot be object-
ively assessed and thus remains questionable.
Unpublished studies in comparison
A total of 5 unpublished studies were detected, corre-
sponding to 31% of the 16 initiated studies (table 1(II)).
Explanations provided for not publishing the results
were obtained for four of the ﬁve studies (80%) and
were loss of interest of the investigator and/or change in
staff. Figure 2 presents the distribution in time of unpub-
lished studies (year of presentation or thesis) compared
with the published studies (year of publication) assum-
ing that unpublished studies would have been published
in the same year or at least not signiﬁcantly later.
Comparing the sizes of unpublished to published
studies, the pool of unpublished studies contains three
studies (US#1:Lehnert TG 1998; US#2:Perez R 2001;
US#5:Gerber M 2003) that are of similar size as the
largest published study (table 1).30 However, it is unclear
whether all patients of unpublished studies did actually
enter the prognostic analysis or whether this represents
the overall pool of, for example, available biopsy results.
Other study characteristics of unpublished studies such
as tumour stage and tumour grade were not remarkably
different from published studies by showing some vari-
ation (table 1). The same holds true for antibodies and
cut-offs used as far as reported (table 2).
Two studies assessed tumour recurrence, two assessed
progression and one assessed both. Altogether, results
Table 1 Continued
Reference (I) or contact person and
year of analysis (II)
Reporting
period*
Study size
(number of
events)
Tumour stage
Tumour grade Surgical treatment
(II) Unpublished studies
Place of reporting institution: Aachen (Germany)
US#1: Lehnert TG (1998) NR 121 (NR) Ta–T4
G1–G3
NR
Place of reporting institution: Erlangen (Germany)
US#2: Perez R (2001) NR 107 (NR) Ta, T1–T2
G1–G3
NR
Place of reporting institution: Heidelberg (Germany)
US#3: Kunkel A (1996) NR 33 (NR) T1
G1–G3
NR
Place of reporting institution: Mainz (Germany)
US#4: Adler J (1998) NR 49 (NR) Ta–T4
G1–G4
NR
Place of reporting institution: Saarbrücken/Homburg (Germany)
US#5: Gerber M (2003) NR 115 (NR) T1–T4
G2–G4
NR
*Reporting period usually refers to the time period of patient inclusion.
†Analysis was only done within two non-overlapping subgroups.
‡Associated (excluded) studies with the respective included study mentioned in row above.
¶Studies assessing two end points.
§Publication in German language.
**Analysis was only done within partly overlapping subgroups (A and B as well as C and D add up to whole study population).
NR not reported; TUR, transurethral resection.
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from seven analyses were reported. Similar to published
studies, only p values or the study’s conclusions are avail-
able. Two of the seven reported analyses presented sig-
niﬁcant results (29%), while all other comparisons
yielded insigniﬁcant results (table 3). See online supple-
mentary table S3 for a detailed overview. Remarkably,
one of the signiﬁcant results was obtained in a study that
also assessed the prognostic impact of p53 in further
separate analyses not revealing any further signiﬁcant
association (US#4:Adler J 1998). There is no informa-
tion available on how the association between outcome
and p53 was statistically assessed.
Overall, collected information is similarly incomplete
as for published studies. The study quality is thus difﬁ-
cult to assess and questionable.
DISCUSSION
Non-publication due to loss of interest
Since the presence of publication bias may lead to incor-
rect interpretation and conclusions of available data/evi-
dence, it is necessary to evaluate the extent and possible
impact of unpublished studies. In this project, we
assessed this problem in the paradigm of p53 as a poten-
tial prognostic factor in bladder cancer in a well-deﬁned
area (all centres in Germany conducting research on the
question of interest) over a representative period of time
(1993–2007). Our approach enabled us to illustrate this
issue in a very speciﬁc setting—maybe for the ﬁrst time.
Our extensive search for published and unpublished
studies revealed 16 studies assessing the prognostic
impact of p53 in bladder cancer of which 11 (69%) have
been published and 5 (31%) have not. Thus, conclu-
sions based on published data alone are prone to publi-
cation bias because the omission of the publication most
likely occurred for some reason and not randomly. In
our project, reasons were loss of interest of the investiga-
tors and/or change in staff. At least to some extent,
both might be related to the conclusion that the study
results were thought to be insufﬁciently innovative or
Table 2 p53 antibodies for immunohistochemistry
Antibody
Reference (I) or contact person
and year of analysis (II) Dilution Cut-off to define positivity
(I) Published studies
AB-6 Jankevicius et al (2002)45 1:100 20%
BP5312 Hake et al (1993)30 NR 10%
CM1 van Ahlen et al (1997)39 NR <20%, 30–80%, >80%*
DO-1 Schmitz-Draeger et al (1997)38 1:100 5%
Wolf et al (2001)44 1:100 20%
DO-7 Rödel et al (2000)41 1:50 10%
Friedrich et al (1997)37 1:100 5%
Leissner et al (2001)43 1:100 20%
pAB1801 Serth et al (1995)36 1:50 20%
Kuczyk et al (1995)34 1:50 40%
Krüger et al (2005)47 1:50 7% (observed median)
(II) Unpublished studies
DO-1 US#1:Lehnert TG (1998) 1:100 <10%, 10–20%, >20%
DO-1 and pAB1801 US#4:Adler J (1998) NR DO-1: 9%, pAB1801: 7.2% (observed medians)
US#5:Gerber M (2003) NR various cut-offs used; eg, 40%
unknown US#2:Perez R (2001) NR various cut-offs used; eg, 25%
US#3:Kunkel A (1996) NR <20%, 20–80%, >80%
*Presumably printing mistake in source publication.
NR: not reported.
Table 3 Final conclusion based on reported analyses of
time-to-event or binary outcomes
Final
conclusion:
significant?
Outcome Studies (n) Yes No
(I) Published studies 11
Overall survival 3 0 3
Cancer-specific survival 2 1 1
Recurrence-free survival 2 1 1
Progression-free survival 4 2 2
Combined end point 2 1 1
Binary end point
(recurrence, progression)
4 2 2
Total number of available
results
17 7 10
(II) Unpublished studies 5
Recurrence 4 2 2
Progression 2 0 2
Combined end point 1 0 1
Total number of available
results
7 2 5
If several results for same outcome using same set of patients
within a study were available, conclusion was drawn from the
analysis that is presumably least biased (eg, multivariable Cox
regression).
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not convincing. As ‘change in staff’ may also be related
to the loss of interest of the research group or may
imply the change of scientiﬁc focus within the research
group, we decided to term it non-publication due to
‘loss of interest’ in general. Similar to previous ﬁndings,
it seems to mainly reﬂect the investigator’s (in)decision
rather than other circumstances such as rejection of the
manuscript by a journal.9 49
The paradigm of p53 as a potential prognostic factor
in bladder cancer appears to be a suitable example to
illustrate this issue. This setting is especially eligible be-
cause of the historical development of marker research
during this period and the restricted number of possible
sites, leading to the feasibility to conduct a retrospective
study. Furthermore, these studies are characterised by a
similar design and similar end points. In addition,
surgery and follow-up is conducted by urologists ensur-
ing a close contact to participants of such studies.
Starting rather promising in the early 1990s, p53 was the
subject of many studies in the last 25 years. Still, the issue
of its prognostic impact in bladder cancer is not settled
even after the conduction of meta-analyses.24 26–28
In the course of the years, some evidence that more
studies have been performed than were eventually
published was accumulated.26 29 It may therefore be
speculated that this loss of interest might have been
intensiﬁed over the years due to the contradictory results
published.
While this project has several intriguing aspects, there
are also some limitations to be discussed: ﬁrst, although
this project is based on extensive and thorough search
for published and unpublished studies including pre-
existing knowledge of these investigations by two authors
(PJG, BJSD), we cannot fully exclude that we may have
missed studies whether published or not. Regarding
published studies, our search strategy in only one elec-
tronic data source (Medline) might not have revealed all
relevant studies. However, the impact of further data
sources on search result was recently shown to be
modest.50 Moreover, the literature search was restricted
to the period from 1993 to 2007 and was not updated
later on because of the complexity to search for unpub-
lished studies. As a consequence, we cannot present
information on the current situation in this ﬁeld.
Misclassiﬁcation of published studies as unpublished was
ruled out by personally contacting responsible study
group members inquiring the publication status. In add-
ition, we may have missed some unpublished studies due
to the incomplete feedback from contacted people and
institutions, incomplete acquisition of abstract books as
well as limited access to university hospital libraries.
Another limitation may be the geographic restriction
to Germany questioning the project’s representativeness
on a larger scale. This step, however, was necessary
because a European or even worldwide search of this
character is impossible. In order to meet the primary
interest of a complete identiﬁcation of published and
unpublished studies in one region rather than on
general representativeness, this approach appears justi-
ﬁed. Although the restriction of a review to such a well-
deﬁned population of studies decreases the number of
studies overall and thus increases the uncertainty when
estimating a combined effect, it also has several metho-
dological advantages. Identifying all studies in a well-
deﬁned population might allow to derive a (nearly)
unbiased estimate and it might offer the option to
conduct IPD meta-analysis, a key issue in a meta-analysis
of observational studies. This idea was already proposed
by Altman in 1983.51
Finally, the paradigm of p53 might be a valid model
choice to assess the extent of unpublished studies and
their impact in biomarker research but may not be rep-
resentative for other areas of medical research.
Non-publication and publication bias in medical research
Non-publication of study results is a general issue in
medical research. Chalmers and Glasziou stated in 2009
that over 50% of the studies in biomedical research were
not fully published and thus represent avoidable waste
of research evidence.11 As consequence, published
results might be affected by publication bias leading to
an overestimation of the true effect.12–15 In prognostic
cancer research, a respective survey revealed that nearly
all included articles reported signiﬁcant results.17
Unfortunately, the described history of p53 is not
uncommon in the ﬁeld of biomarker research. Despite
Figure 2 Published and
unpublished studies over time.
For published studies, the year of
publication is presented; for
unpublished studies, the year of
presentation at a congress (or
similar) or the year of dissertation
is presented. We assume that
publication of unpublished results
would have been not much later
but at least within our considered
time frame (up to 2007).
8 Sekula P, et al. BMJ Open 2016;6:e009972. doi:10.1136/bmjopen-2015-009972
Open Access
group.bmj.com on November 3, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
the postulated clinical usefulness of biomarkers in
general, most biomarkers do not enter clinical practice
giving raise to several publications discussing this situ-
ation and evaluating the reasons.52–55 Since marker
research and especially immunohistochemistry appear to
be simple to perform and interpret and guidelines on
this type of research are still not implemented, it is also
assumed that non-publication occurs more frequently
than, for example, in the area of randomised clinical
trials assessing therapeutic effects.56
Past studies assessing non-publication applied several
approaches to identify unpublished studies: one indirect
way to assess it was to compare results of scientiﬁc
reports to non-scientiﬁc communications such as news-
paper articles.14 A more direct way is the approach to
identify study groups or single people working in the
ﬁeld using large databases such as Medline or via
related publications or with the help of membership lists
of related organisations and, subsequently, to directly ask
investigators whether they have knowledge of unpub-
lished studies.29 57 Although this approach is rather
straightforward, some unpublished studies conducted,
for example, by single researchers or smaller research
groups (new or less active in the ﬁeld and thus not
present in the databases) might be missed. Another
approach is the identiﬁcation and the evaluation of the
status of studies indicated to ethics committees, review
boards, funding bodies or trial registries.58–61 Although
registries will become more exhaustive in the future,
those sources are momentarily very limited in their
content of observational studies. Moreover, the com-
pleteness of such sources may not be reliably available
for any area of medical research.
In order to circumvent the majority of the caveats
mentioned before, we used a composed approach to
identify unpublished studies addressing the same spe-
ciﬁc research question in Germany. On the one hand,
we used several of the methods applied in the past by
taking advantage of different sources including the
search in Medline as well as programmes and congress
proceedings to identify people and study groups
working in the ﬁeld. The list was then further extended
by directly addressing urologic departments and an
investigation of university libraries. Moreover, we used
the knowledge of two of us (PJG, BJSD) about the
research ﬁeld and the general research structure in
Germany. Altogether, for p53 as a potential prognostic
marker in bladder cancer, our strategy provides a com-
prehensive overview of published and unpublished
studies in the given time period in Germany. The
described method may provide a new transparent tem-
plate to perform this type of research.
Can we summarise the effect of p53?
Since the discussion on the relevance of p53 as a prog-
nostic marker in bladder cancer is still under debate,
the question arises whether unpublished studies would
change the current understanding and interpretation of
the data.26 27 One of the initial aims was to identify all
relevant additional studies (including their evidence)
and to evaluate their attributable effect on the evidence
we have from the interpretation of published results.
While we were successful with regard to the retrieving of
the completeness of p53 work in this period in
Germany, we failed to gather sufﬁcient valid and com-
parable (individual patient) data for the anticipated
comparison. As a meaningful meta-analysis of the
obtained data is not possible, the current study cannot
address the impact of unpublished studies on the inter-
pretation of the evidence of p53 as a prognostic marker.
However, since published and unpublished studies do
not show larger differences in their characteristics and
results, it could be speculated that there would be no
general change in the judgement of p53 as prognostic
marker if unpublished results had been reported and
thus implemented in a comprehensive analysis.
Reasons for not being able to provide a meaningful
combined estimate in the current study are manifold:
ﬁrst, there is the issue that studies are poorly reported
which makes the assessment of study quality and inter-
pretation of results difﬁcult and sometimes impossible.
This includes a poor description of the study and an
insufﬁcient report of the conducted analysis and its
results. For example, only two of the six published
studies that used Cox regression in their analysis
reported effect estimates. Thus, a meta-analysis based on
effect estimates is not meaningful. Alternatively, one may
try to combine reported p values. But even this kind of
analysis—of questionable value—is not feasible because
most of the authors did not list p values for assessed end
points. Poor reporting of study results, however, is a
general issue in medical research and not limited to the
presented work. For cancer prognostic studies empirical
evidence has been provided.62 Second, the large hetero-
geneity between studies questions the usefulness of a
combined estimate in general. This conclusion is based
on observed differences in patient populations, method-
ology (eg, usage of different antibodies in different dilu-
tions, different cut-offs), end points and statistical
methods.
Another aspect often overlooked is that studies are fre-
quently too small to provide any reliable result.26 The
general issue of small sample sizes of studies was very
well illustrated in a review on tumour markers in neuro-
blastoma.63 The identiﬁed studies of our project are no
exception. The population sizes of published and
unpublished studies vary between 30 and 119 patients.
The number of events, which reﬂects the effective
sample size in studies with a survival outcome, was even
much smaller with values ranging from 11 to 63. None
of the included studies provided rationale for sample
sizes. Consequently, the power of studies is assumed to
be limited. Subgroup analyses are not sensible.
Unfortunately, the largest of the published studies
included (overall 119 patients, 61 events) only reports
subgroup analyses.30
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Improvement of biomarker research
In general, our project on p53 illustrates quite impres-
sively the necessity to improve the general situation in
prognostic research regarding design and conduction of
studies including their statistical analysis and reporting.
As there is a long way until a biomarker may reach clin-
ical use, different aspects have to be considered depend-
ing on the phase of biomarker research; standards must
be developed and applied.64–66
Fortunately, the last decade has seen several important
contributions, in particular regarding reporting health
research. Following the example of the Consolidated
Standards of Reporting Trials (CONSORT) guidelines
for randomised controlled trials, reporting guidelines
have been developed for many types of observational
studies.67 For tumour marker studies, the Reporting
Recommendations for Tumor Marker Prognostic Studies
(REMARK) guideline including a 20-items checklist was
introduced in 2005 and detailed explanations and ela-
borations of these items were published later.68 69 Good
reporting is an issue which could be easily improved by
following the guidelines, but many more issues are rele-
vant and some of them are either discussed controver-
sially or are a challenge for research. The PROGnosis
RESearch Strategy (PROGRESS) group (http://
progress-partnership.org/) published a series of articles
to provide a framework on different aspects in prognos-
tic research.70–73
In addition, the large proportion of unpublished
studies detected in our project also underlines the
necessity of a preregistration of any study, whether inter-
ventional or observational.3 7 74–77 Prospective registra-
tion of all studies helps not only to quantify the extent
of unpublished (or not yet published) studies. It was
even demonstrated that it helps to improve study design
and methodology.78 Moreover, published protocols may
allow an assessment of studies included into a systematic
review regarding risk of bias in a more sufﬁcient way.79
Currently, study registration is only obligatory for inter-
ventional trials and optional for observational studies,
the usual design in prognostic research.
Also concerning suitable statistical analyses, substantial
contributions for its improvement have been made
recently. Unfortunately, many of these developments are
ignored in practice and methods with known weaknesses
are still used.56 69 Aiming to derive guidance documents
for key issues of the analysis of observational studies, the
STRengthening Analytical Thinking for Observational
Studies (STRATOS) initiative (http://www.stratos-initiative.
org/) was founded recently.80
Finally, to derive a summary assessment for a marker
of interest, it is obvious that a systematic review and a
meta-analysis are required.7 Whereas IPD meta-analyses
of prognostic factors studies have been the exception
10 years ago, several collaborative groups have impres-
sively shown that IPD meta-analyses are possible and that
such projects may provide deeper insight into the role
of a prognostic factor of interest.3 81 However, when
starting such a review project, many aspects, especially
regarding the deﬁnition of well-deﬁned population of
studies, need to be considered.
Conclusion
Altogether, our strategy provides a comprehensive over-
view of published and unpublished studies on p53 as a
potential prognostic marker in bladder cancer in the
given time period in Germany. The described method
may provide a new transparent template to perform this
type of research.
Using a well-deﬁned cohort of studies, we could
provide empirical evidence of non-publication mainly
caused by loss of interest of the investigators. This survey
suggests that about 30% of the studies were not pub-
lished despite the fact that there were no larger differ-
ences between published and unpublished studies.
We consider p53 as a speciﬁc example, but the critical
issues of non-publication and bad reporting are very similar
for research investigating prognostic factors in other dis-
eases. Brieﬂy, we point to some recent initiatives which have
been started to improve on this frustrating situation.
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